The present study aims to evaluate the electromyographic activity of the masseter muscle in patients diagnosed with bruxism using botulinum toxin type A. Thirty female patients, 18 to 40 years-old, with a history of bruxism were randomized into two groups: a Control group (n = 15) that received saline, and a botulinum toxin A (BXT-A) group (n = 15) (Botox�, Allergan Pharmaceuticals LTDA), the solutions were applied to the masseter muscle. The patients were evaluated at Baseline and at 30, 60, 90, 120, 150 and 180 days. At this time, the research subjects were submitted to electromyographic evaluation (EMG System of Brazil 830 C - EMG System of Brazil LTDA, S�o Jos� dos Campos, SP, Brazil). Data were analyzed using two-way ANOVA (p <0.05). The EGM in the BTX-A Group showed significantly lower values than the Control Group 30, 60 and 90 days after application. In the BTX-A group of the left and right masseter muscle, a positive correlation was observed between time and electromyographic activity (Coef: 0.322; P = 0 <0.001) and (Coef: 0.431; P <0.001). The use of botulinum toxin type A in patients with bruxism leads to reduced muscle activity in the first ninety days after application.

Login to Download PDF

Please login with your Paper ID and password to access the full PDF.

🔑 Login to Download